WEKO3
アイテム
{"_buckets": {"deposit": "0d21095a-5f3d-49fa-9b88-144490047246"}, "_deposit": {"created_by": 1, "id": "77532", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "77532"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00077532", "sets": ["29"]}, "author_link": ["804575", "804576", "804581", "804572", "804573", "804571", "804574", "804577", "804579", "804580", "804583", "804582", "804578", "804570"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2019-11-15", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Targeted α-particle therapy is a promising option for patients with malignant pheochromocytoma. Recent observations of α-emitting meta-[At-211]-astato-benzylguanidine ([At-211]-MABG) in a pheochromocytoma mouse model showed a strong anti-tumor effect [1], though the molecular mechanism remained elusive. Here, we show the comprehensive RNA-sequencing (RNA-seq) data for rat pheochromocytoma cell line PC12 cells based on in vitro [At-211]-MABG administration experiments. Enrichment analysis of differentially expressed genes (DEGs) and analysis of the gene expression profiles of cell cycle checkpoints revealed the mode of cell death via the p53-p21 signaling pathway after [At-211]-MABG treatment. Only p53-targeted genes were ranked among representative DEGs for decreased survival at all time points. Also, we estimated the low fluence rate of α-particles in in vitro [At-211]-MABG administration, approximately “one α-particle emission per one cell in one hour” for 10% survival. Long-lasting p53-induced signaling may break the wall of the “low fluence rate” in PC12 tumor cell death to exert anti-tumor effects. We recently published these findings on RNA-seq of in vitro PC12 transcriptome, suggesting that p53-p21 signaling pathway was an important cell death mechanism in anti-tumor effect of [At-211]-MABG [2].\n\nReferences: \n[1] Y. Ohshima et al., Eur J Nucl Med Mol Imaging, 2018. \n[2] Y. Ohshima et al., Theranostics, 2019", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "日本放射線影響学会第62回大会", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "坂下, 哲哉"}], "nameIdentifiers": [{"nameIdentifier": "804570", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "大島, 康宏"}], "nameIdentifiers": [{"nameIdentifier": "804571", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "河野, 暢明"}], "nameIdentifiers": [{"nameIdentifier": "804572", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "横田, 裕一郎"}], "nameIdentifiers": [{"nameIdentifier": "804573", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "渡辺, 茂樹"}], "nameIdentifiers": [{"nameIdentifier": "804574", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐々木, 一郎"}], "nameIdentifiers": [{"nameIdentifier": "804575", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石岡, 典子"}], "nameIdentifiers": [{"nameIdentifier": "804576", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "荒川, 和晴"}], "nameIdentifiers": [{"nameIdentifier": "804577", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakashita, Tetsuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "804578", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oshima, Yasuhiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "804579", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yokota, Yuuichiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "804580", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Watanabe, Shigeki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "804581", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sasaki, Ichiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "804582", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishioka, Noriko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "804583", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/77532", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-09-10"}, "publish_date": "2019-09-10", "publish_status": "0", "recid": "77532", "relation": {}, "relation_version_is_last": true, "title": ["Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway"], "weko_shared_id": -1}
Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway
https://repo.qst.go.jp/records/77532
https://repo.qst.go.jp/records/77532f822f942-bfba-4294-8a77-8f09b4d7feea
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-09-10 | |||||
タイトル | ||||||
タイトル | Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
坂下, 哲哉
× 坂下, 哲哉× 大島, 康宏× 河野, 暢明× 横田, 裕一郎× 渡辺, 茂樹× 佐々木, 一郎× 石岡, 典子× 荒川, 和晴× Sakashita, Tetsuya× Oshima, Yasuhiro× Yokota, Yuuichiro× Watanabe, Shigeki× Sasaki, Ichiro× Ishioka, Noriko |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Targeted α-particle therapy is a promising option for patients with malignant pheochromocytoma. Recent observations of α-emitting meta-[At-211]-astato-benzylguanidine ([At-211]-MABG) in a pheochromocytoma mouse model showed a strong anti-tumor effect [1], though the molecular mechanism remained elusive. Here, we show the comprehensive RNA-sequencing (RNA-seq) data for rat pheochromocytoma cell line PC12 cells based on in vitro [At-211]-MABG administration experiments. Enrichment analysis of differentially expressed genes (DEGs) and analysis of the gene expression profiles of cell cycle checkpoints revealed the mode of cell death via the p53-p21 signaling pathway after [At-211]-MABG treatment. Only p53-targeted genes were ranked among representative DEGs for decreased survival at all time points. Also, we estimated the low fluence rate of α-particles in in vitro [At-211]-MABG administration, approximately “one α-particle emission per one cell in one hour” for 10% survival. Long-lasting p53-induced signaling may break the wall of the “low fluence rate” in PC12 tumor cell death to exert anti-tumor effects. We recently published these findings on RNA-seq of in vitro PC12 transcriptome, suggesting that p53-p21 signaling pathway was an important cell death mechanism in anti-tumor effect of [At-211]-MABG [2]. References: [1] Y. Ohshima et al., Eur J Nucl Med Mol Imaging, 2018. [2] Y. Ohshima et al., Theranostics, 2019 |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 日本放射線影響学会第62回大会 | |||||
発表年月日 | ||||||
日付 | 2019-11-15 | |||||
日付タイプ | Issued |